Details of Disease

General Information of Disease (ID: DISVC11M)

Disease Name	Castleman's disease
Synonyms	ALNH; angiofollicular ganglionic hyperplasia; Castleman disease; lymphoid hamartoma; angiofollicular lymph hyperplasia; AFLH; angiofollicular lymphoid hyperplasia; Castleman's disease; giant lymph node hyperplasia; GLNH; Castleman's tumor; angiofollicular lymph node hyperplasia; Castleman's tumour
Disease Class	4B2Y: Castlemans disease
Definition	Castleman disease (CD) is a benign lymphoproliferative disorder that may present as a localized or multicentric form. The clinical manifestations are heterogeneous, ranging from asymptomatic discrete lymphadenopathy to recurrent episodes of diffuse lymphadenopathy with severe systemic symptoms.
Disease Hierarchy	DISMVL8O: Lymphoproliferative syndrome DISVC11M: Castleman's disease
ICD Code	ICD-11 ICD-11: 4B2Y
Disease Identifiers	MONDO ID MONDO_0015564 MESH ID D005871 UMLS CUI C0017531 MedGen ID 42211 Orphanet ID 160 SNOMED CT ID 207036003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 3 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ibudilast	DM4LSPN	Approved	Small molecular drug	[1]
Siltuximab	DMGEATB	Approved	Antibody	[2]
Tocilizumab	DM7J6OR	Approved	Monoclonal antibody	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 1 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MLYCD	TT9Z4YD	Strong	Biomarker	[4]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CD48	OT83ZNPP	Strong	Biomarker	[5]
IL6R	OTCQL07Z	Definitive	Biomarker	[6]
------------------------------------------------------------------------------------

References

1	Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
2	Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 Aug;15(9):966-74.
3	Interleukin-6: A Masterplayer in the Cytokine Network. Oncology. 2020;98(3):131-137.
4	Quantitative analysis of a rare disease network's international contact database and E-repository provides insights into biobanking in the electronic consent era.Orphanet J Rare Dis. 2019 Jul 11;14(1):173. doi: 10.1186/s13023-019-1145-y.
5	Clinical, laboratory and imaging findings in Castleman's disease - The subtype decides.Blood Rev. 2018 May;32(3):225-234. doi: 10.1016/j.blre.2017.11.005. Epub 2017 Nov 29.
6	The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.BMC Nephrol. 2018 Oct 11;19(1):263. doi: 10.1186/s12882-018-1065-4.